Last Updated: June 9, 2026

Details for Patent: RE46363


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent RE46363 protect, and when does it expire?

Patent RE46363 protects OZEMPIC and is included in one NDA.

This patent has nineteen patent family members in fifteen countries.

Summary for Patent: RE46363
Title:Dial-down mechanism for wind-up pen
Abstract:The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising dial-up cam arranged to receive and engage with a dial-up key, wherein the dial-up cam and the dial-up key are adapted to, upon rotation of a dose setting member in a first direction, cooperate to strain the torsion spring of the injection device, and a dial-down cam arranged to receive and engage with a dial-down key, wherein the dial-down cam and the dial-down key are adapted to, upon rotation of the dose setting member in a second direction, cooperate to release the torsion spring of the injection device, the second rotation direction being opposite to the first rotation direction.
Inventor(s):Claus Schmidt Moeller, Christian Peter Enggaard, Bo Radmer, Tom Hede Markussen
Assignee: Novo Nordisk AS
Application Number:US14/091,774
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent RE46363
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;
Patent landscape, scope, and claims:

United States RE46363 (Dial-down Mechanism for Wind-Up Injection Devices): Scope, Claim Strength, and Landscape

RE46363 is a U.S. reissue patent tied to a wind-up (torsion-spring) injection device dial mechanism that uses opposing “dial-up” and “dial-down” cam/key interactions to respectively strain and then release a torsional spring as a user rotates a dose setting element in opposite directions. The core claim set focuses on (i) a dial-down release that is structurally coupled to the same cam-track regions used for dial-up straining, (ii) a cam-and-key architecture in which both dial-up and dial-down keys reside on a single arm, and (iii) track geometries (curved, V-shaped) and multi-cam variants.

The claims below are directed to both the mechanism and the device, with an additional method claim set out for operation of a wind-up injection pen.


What does RE46363 claim, in plain mechanical terms?

Claim 1 (independent): Dial-up and dial-down cams on the same track region with single-arm keys

Claim 1 defines a dial-down mechanism for an injection device with a torsion spring:

  • Energy storage and release

    • A torsion spring (18) assists injection of a medicament dose.
    • Dial-up cam (15) receives and engages a dial-up key (11) to strain the torsion spring when the dose setting member rotates in a first direction.
    • Dial-down cam (16) receives and engages a dial-down key (12) to release the torsion spring when the dose setting member rotates in a second direction, opposite the first.
  • Same-track requirement (structural constraint)

    • dial-up and dial-down cams form part of regions of the same track
    • This is a strict co-location constraint: a later-infringement argument can turn on whether the dial-up and dial-down features are implemented on a common track body or separate tracks.
  • Single arm carrying both keys

    • further comprising an arm wherein the dial-up and dial-down keys are both located on the same arm
    • The dial-up key and dial-down key are not independent actuators on different members; they are mounted on one arm.
  • Engagement roles

    • Upon dial-up rotation: cam/key geometry drives spring straining.
    • Upon dial-down rotation: cam/key geometry allows spring release.

This claim is the pivot point for both scope (what is covered) and design-around (what must change).

Dependent claims: Track geometry and multi-cam/key architectures

Dependent claims narrow or extend Claim 1:

  • Claim 2: Dial-up cam (15) is part of a curved track.
  • Claim 3: The curved track is circular, elliptical, or parabolic.
  • Claim 4-5: Two dial-up cams/keys:
    • Claim 4 adds a first and second dial-up cam.
    • Claim 5 adds a first and second dial-up key, each engaging its corresponding dial-up cam.
  • Claim 6: Dial-down cam (16) is part of a V-shaped track.
  • Claim 7-8: Two dial-down cams/keys:
    • Claim 7 adds first and second dial-down cam.
    • Claim 8 adds first and second dial-down key, each cooperating with its corresponding dial-down cam.

Device claim and use claim

  • Claim 9: “A medication delivery device” comprising the dial-down mechanism of Claim 1.
  • Claim 10: The device is a handheld medication injection pen.
  • Claim 11 (method): Wind-up injection pen method:
    • Rotate a first element in a “dial up direction.”
    • Rotate a second element in the same direction.
    • Strain a torsional spring.
    • Move an arm engaged with an edge to a neighboring edge, and when engaged, it prevents unwinding.
    • Rotate in the opposite direction (“dial down”).
    • Move a pick-up key and radially lift the arm out of engagement with the edge.
    • When fully disengaged, allow the second rotatable element to rotate in the second direction and decrease spring strain.

This method claim operationalizes the same arm/edge/engagement logic that is structurally claimed in Claim 1.


What is the claim scope and where is infringement likely to concentrate?

1) Strongest coverage hinge: single-arm dual-key architecture plus same-track

Claim 1 requires both:

  • the dial-up and dial-down keys are on the same arm, and
  • the dial-up and dial-down cams “form part of regions of the same track.”

In infringement analysis, these two limitations typically act as the most meaningful constraints. A competitor can avoid Claim 1 by altering either:

  • the mounting concept (keys on separate arms or separate linkages), or
  • the track architecture (dial-up and dial-down on separate track bodies rather than “same track regions”).

2) Directional rotation and functional coupling is built into the cam/key cooperation

The claim is not just “there are cams.” It requires:

  • dial-up rotation strains torsion spring via dial-up cam/key cooperation; and
  • opposite dial-down rotation releases via dial-down cam/key cooperation.

That creates an argument structure around whether a given design truly uses opposite rotational input to respectively strain and release via the recited cam/key pairs.

3) Track shape narrowing in dependent claims

Dependent claims add track geometry limitations:

  • Claim 2-3 constrain dial-up track to curved shapes, with a defined family (circular/elliptical/parabolic).
  • Claim 6 constrains dial-down track to V-shaped.
  • Claims 4-5 and 7-8 expand to two-cam/two-key variants.

Practically, these dependent limitations matter most when:

  • a competitor’s mechanism matches the core Claim 1 concept but differs in track form; or
  • a competitor uses multiple cams/keys; then the dependent claim set may capture that variation.

How do the dependent claims map to real design features?

Dependent claim matrix

Claim Limitation added Functional consequence Likely relevance in FTO
2 Dial-up cam part of curved track Controls how cam profile strains spring Medium (geometry may be changed without abandoning function)
3 Curved dial-up cam track is circular/elliptical/parabolic Limits mathematical geometry family Medium-low (often redesignable)
4-5 Two dial-up cams and two dial-up keys Potentially increases control steps or load distribution Medium (only if competitor uses multi-cam dial-up)
6 Dial-down cam part of V-shaped track Enables a release transition shape Medium (V-shaped tracks are common enough but still a constraint)
7-8 Two dial-down cams and two dial-down keys Multi-stage release profile or robustness Medium (only if competitor uses multi-cam dial-down)
9-10 Device and pen implementation Captures products implementing Claim 1 High (once mechanism matches, device claim becomes a broad backstop)
11 Method sequence using arm lifting/pick-up key and edge-to-edge movement Provides process capture of functional cycle Medium (process infringement requires matching operation steps)

What design-arounds are most plausible based on the claim text?

A) Break the “same arm” requirement

Claim 1 demands both dial-up and dial-down keys are on the same arm. A design that places dial-up and dial-down keys on different arms, different carriers, or uses independent linkages can be positioned to avoid this limitation.

B) Break the “same track regions” requirement

The claim’s track constraint is specific: dial-up and dial-down cams are part of regions of the same track. A design that uses:

  • separate tracks, or
  • a track with distinct bodies/components rather than a single continuous track region can target a non-equivalence argument on structural placement.

C) Modify track geometry to escape dependent claims

Even if Claim 1 remains in play, dependent claims are narrower:

  • remove curved dial-up track geometry from the circular/elliptical/parabolic families; and/or
  • remove a V-shaped dial-down track profile.

This can preserve non-infringement as to dependent claims, even if Claim 1 is hard to avoid.

D) Change the functional release sequence (method claim focus)

Claim 11 describes a specific operational sequence:

  • strain and edge-to-edge stepping with arm preventing unwinding,
  • opposite rotation,
  • pick-up key radially lifting the arm out of engagement,
  • then spring strain decreases.

A mechanism that releases via a different disengagement mode or without the recited pick-up/radial lift step can narrow process exposure even if product mechanics still resemble the core mechanism.


What is the likely competitive target: wind-up injection pens with torsion spring dial mechanism?

RE46363 is anchored to the wind-up pen paradigm where:

  • the user dials dose by rotating a dose setting member,
  • the device uses a torsion spring to provide mechanical energy to drive injection,
  • the dose setting involves energy storage (dial-up) followed by an opposite direction release/unlock (dial-down).

That scope tends to overlap with common pen architectures used in:

  • dose setting mechanisms that include cam-based retention and release;
  • mechanisms using “dial-up” and “dial-down” behaviors with opposing rotational directions.

The unique part here is the specific cam/key arrangement:

  • both dial-up and dial-down cam/key interactions tied to torsion spring straining and release; and
  • same track regions plus single arm holding both keys.

How does RE46363 fit into the broader patent landscape (US reissue + injection pen mechanisms)?

Landscape structure for analysis

For business decisions, the practical landscape is built around three “rings”:

  1. Core mechanical architecture patents

    • Torsion-spring wind-up pens
    • Cam-based dose setting
    • Latching/unlatching and release under opposite rotation
  2. Dial-down specific patents

    • Mechanisms that explicitly create a “dial-down” behavior to release stored energy
    • Cam track and key arrangements controlling the transition
  3. Edge/arm/pick-up and disengagement details

    • Stepwise engagement along an edge
    • Radial lifting or disengagement actions
    • Multi-stage cams and keys

RE46363 sits across rings 1-3 by simultaneously claiming:

  • torsion spring straining and release via dial-up and dial-down cams/key cooperation, and
  • a specific mechanical coupling (same-track region and keys on a single arm), plus
  • an edge/arm/pick-up sequence in the method claim.

Where competitors usually cluster risk

Competitors are typically at highest risk when their pen has:

  • a single carrier/arm that drives both charging and release;
  • a single cam-track body or contiguous track portion that supports both states; and
  • an operational cycle that mirrors a lock-retain-unlock sequence during opposite rotation.

Competitors are typically at lower risk when they:

  • use separate mechanisms for charging and release,
  • isolate dial-up and dial-down on distinct track elements/bodies, or
  • redesign key/arm interfaces so that both keys are not co-located on one arm.

Enforceability and claim leverage: what the claims enable in practice

1) Product claims support direct infringement paths

  • Claim 9 captures “a medication delivery device” that includes the dial-down mechanism.
  • Claim 10 narrows to “handheld medication injection pen,” which aligns to the product category most likely to be sold into the market.

If the mechanism matches Claim 1, these device claims support direct product infringement arguments.

2) Method claim expands use-based capture

Claim 11 provides a method sequence for using a wind-up injection pen. In enforcement posture, method claims can be used to:

  • support inducement or contributory theories in certain contexts, and
  • create additional exposure if the accused party’s device and user procedure align tightly with the claimed steps.

3) Dependent claim coverage supports incremental differentiation

The dependent claims provide fallback positions:

  • even if a design differs in track shape,
  • multi-cam variants or specific track profiles can still be targeted depending on actual engineering.

RE46363 claim-by-claim scope summary (as provided)

  1. Independent: Dial-down mechanism with torsion spring, dial-up and dial-down cams receiving respective keys, opposite rotation to strain and release, dial-up and dial-down cams on same track regions, both keys on same arm, with cam/key cooperation.
  2. Dial-up cam in curved track.
  3. Dial-up curved track is circular/elliptical/parabolic.
  4. Two dial-up cams.
  5. Two dial-up keys each engaging corresponding dial-up cams.
  6. Dial-down cam in V-shaped track.
  7. Two dial-down cams.
  8. Two dial-down keys each engaging corresponding dial-down cams.
  9. Medication delivery device with dial-down mechanism of Claim 1.
  10. Handheld injection pen.
  11. Wind-up injection pen method using dose direction rotation, torsion straining, arm edge engagement to prevent unwinding, opposite rotation releasing via pick-up key radially lifting arm out of engagement, decreasing spring strain.

Key Takeaways

  • RE46363 Claim 1 is centered on a torsion-spring wind-up injection pen dial mechanism that uses opposing rotational directions to strain (dial-up) and release (dial-down) via dial-up/dial-down cam/key cooperation.
  • Two structural limitations likely drive infringement and design-around: (i) dial-up and dial-down cams must be on “regions of the same track,” and (ii) both dial-up and dial-down keys must be on the same arm.
  • Dependent claims then constrain track geometry (curved; circular/elliptical/parabolic; V-shaped) and cover multi-cam/multi-key variants.
  • Product claims (Claims 9-10) broaden enforcement to devices, while the method claim (Claim 11) adds exposure tied to a specific operational sequence of edge engagement and radial lifting to disengage.

FAQs

1) Is RE46363 limited to a specific torsion spring injection pen layout?

It is limited to an injection device with a torsion spring assisted injection system and a dial mechanism where dial-up and dial-down cams/key cooperation respectively strain and release that spring via opposite dose-setting rotations.

2) What is the most important limitation for a design-around?

The claim’s requirement that the dial-up and dial-down keys are both located on the same arm, coupled with the requirement that dial-up and dial-down cams form regions of the same track.

3) Do dependent claims materially narrow the scope?

Yes. They narrow into track-geometry families (curved/circular-elliptical-parabolic for dial-up; V-shaped for dial-down) and multi-cam/key configurations.

4) Does RE46363 cover both the mechanism and the pen product?

Yes. It includes a mechanism claim (Claim 1) and device claims (Claims 9-10), including handheld injection pens.

5) Does RE46363 include method protection?

Yes. Claim 11 recites a wind-up injection pen use cycle, including edge-to-edge arm engagement, opposite rotation, and disengagement by a pick-up key with radial lifting.


References

[1] RE46363, United States Patent Reissue, claims as provided in prompt (dial-down mechanism for wind-up injection pen with torsion spring, dial-up and dial-down cams/keys, same track regions, single-arm keys, and method claim).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent RE46363

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-001 Dec 5, 2017 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-004 Oct 6, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-002 Apr 9, 2019 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE46363

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04077900Oct 21, 2004
PCT Information
PCT FiledOctober 20, 2005PCT Application Number:PCT/EP2005/011285
PCT Publication Date:May 04, 2006PCT Publication Number: WO2006/045526

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.